Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan

Journal of Medical Economics

Volumn 16, Issue 5, 2013, Pages 667-677

  Garris, Cindy ^a   Jhingran, Priti ^a   Bass, Damon ^a   Engel Nitz, Nicole M ^b   Riedel, Aylin ^b   Dennis, Greg ^a,c  

^a GLAXOSMITHKLINE   (United States)

^b OPTUM   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Cost of illness; Disease burden; Lupus; Managed care; Resource utilization; SLE; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB;

ADULT; ALGORITHM; ARTICLE; COHORT ANALYSIS; COST OF ILLNESS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; EMERGENCY CARE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADOLESCENT; ADULT; ALGORITHMS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PATIENT ACUITY; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84876405523     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.778270     Document Type: Article

References (41)

1. Naleway AL, Davis ME, Greenlee RT, et al. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 2005;14:862-6 (Pubitemid 41597626)
2. Uramoto KM, Michet CJ, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50 (Pubitemid 29042569)
3. Balluz L, Philen R, Ortega L, et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am J Epidemiol 2001;154:1029-36 (Pubitemid 33121621)
4. Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007;56:2092-4 (Pubitemid 47110409)
5. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010;69:1603-11
6. Pons-Estel GJ, Alarcon GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68
7. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet 2007;369:587-96 (Pubitemid 46241445)
8. Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009;51:66-79
9. Campbell Jr R, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum 2008;59:458-64 (Pubitemid 351563526)
10. Scofield L, Reinlib L, Alarcon GS, et al. Employment and disability issues in systemic lupus erythematosus: a review. Arthritis Rheum 2008;59:1475-9
11. Campbell Jr. R, Cooper GS, Gilkeson GS. The impact of systemic lupus erythematosus on employment. J Rheumatol 2009;36:2470-5
12. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006;15:633-43 (Pubitemid 44682824)
13. Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009;38:121-7
14. Panopalis P, Tazdany J, Gillis JZ, et al. Health care costs and costs associated with change in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008;59:1788-95
15. Yelin E, Tonner C, Trupin L, et al. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample. Arthritis Rheum 2009;61:247-58
16. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7 (Pubitemid 44205016)
17. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-90 (Pubitemid 36819418)
18. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009;5:400-4
19. Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54-9
20. Ruperto N, Hanrahan LM, Alarcon GS. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62
21. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30: 1955-9 (Pubitemid 37075543)
22. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine 2006;85:147-56 (Pubitemid 43833013)
23. Rivest C, Lew RA, Welsing PM, et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol 2000;27:680-4 (Pubitemid 30151346)
24. Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27: 377-9 (Pubitemid 30095467)
25. Kalunian K, Merrill JT. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin 2009;25:1501-14
26. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8 (Pubitemid 30642567)
27. Zhu TY, Tam LS, Lee VW, et al. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009;61:1159-67
28. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40
29. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of 6 systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18 (Pubitemid 19237865)
30. Isenberg DS, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus arythematosus. Rheumatology 2005;44:902-6 (Pubitemid 41511186)
31. Bureau of Labor Statistics. US Department of Labor, Consumer Price Index, Chained Consumer Price Index. Washington, DC. 2009 http://www.bls.gov/data/. Accessed 10 September 2009
32. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;1:153-71 (Pubitemid 29052479)
33. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-9
34. Pelletier EM, Ogale S, Yu E, et al. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009;31:2653-64
35. Li T, Carls GC, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009;61:755-63
36. Zhu TY, Tam LS, Lee VW, et al. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol 2010;37:568-73
37. Brunner HI, Sherrard TM, Klein-Gitelman MS. Cost of treatment of childhoodonset systemic lupus erythematosus. Arthritis Rheum 2006;55:184-8
38. Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2012;64:132-7
39. Sutcliffe N, Clarke AE, Taylor R, et al. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:37-47
40. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2011;63:751-60
41. Zhu TY, Tam LS, Lee VW, et al. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009;48:564-8